Pharmaceuticals, Biotechnology & Life Sciences

Vimta Labs Q1 FY 2026‑27 shows resilient growth across pharma, clinical, and testing services, with a new biologics facility securing its first order.

Paradigm Biocapital’s stake boost in Jade Biosciences signals strong confidence in its precision oncology pipeline and partnership network, offering investors a rare glimpse into biopharma’s next‑generation therapeutic opportunities.

See why Sartorius AG’s first‑half results show strong margins but slower revenue growth—what investors and healthcare tech leaders need to know for 2024.

Pfizer’s July 2026 ex‑dividend and new Serina Therapeutics partnership reveal a strategy that balances shareholder returns with cutting‑edge drug‑delivery tech, positioning the company for long‑term growth.

Legal showdown: Novo Nordisk sues Eli Lilly over misleading weight‑loss ads, demanding a court order to stop comparative claims and protect market share in the $100 billion obesity‑drug race.

Danaher Corp’s 7.5% share surge shows investors re‑value its strong innovation, operational efficiency and growth‑fueled earnings – a rare upside in today’s market.

Sanofi drops eczema drug Amlitelimab after data shows it can’t beat Dupixent, while Regeneron keeps pushing gene‑editing TSRA‑196—showing how data‑driven realignment and partnership‑focused innovation reshape biopharma strategy.

First‑half 2026 results show Sartorius Stedim Biotech’s recurring consumables driving steady revenue growth, tariff‑adjusted margins, and Asia‑Pacific momentum for 2026.

Discover how WuXi AppTec’s booming weight‑loss manufacturing contracts are driving 2026 earnings, market expansion, and investor confidence in the Chinese CDMO sector.

West Pharmaceutical Services Q2 2026: $800 M net sales, $2.00+ EPS, strong cash flow, and a mid‑$3 B sales outlook driven by high‑growth injectable drug demand.